Clinical Trials on PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS) in China

Total 1 results

Novartis Pharmaceuticals

Recruiting

Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (EPIK-P2)

PIK3CA-related Overgrowth Spectrum (PROS)

United States, Canada, Spain, Switzerland, France, United Kingdom, Germany, Italy, China, Hong Kong, Netherlands, Norway

3

Subscribe